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had exactly the same predictive value as CORT3. The addition of
baseline LH to CORT3, increased sensitivity to 100.0%, specificity to
88.9%, PPV to 90.4%, and NPV to 100.0%.
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Abstract: The insulin tolerance test (ITT) is the gold standard for
diagnosing adrenal insufficiency (AI) after pituitary surgery. The ITT is
unpleasant for patients, requires close medical supervision and is
contraindicated in several comorbidities. The aim of this study was
to analyze whether tumor size, remission rate, preoperative, and early
postoperative baseline hormone concentrations could serve as predic-
tors of AI in order to increase the diagnostic accuracy of morning serum
cortisol.
This prospective study enrolled 70 consecutive patients with newly
diagnosed pituitary adenomas. Thirty-seven patients had nonfunction-
ing pituitary adenomas (NPA), 28 had prolactinomas and 5 had soma-
totropinomas. Thyroxin (T4), thyrotropin (TSH), prolactin, follicle-
stimulating hormone (FSH), luteinizing hormone (LH), testosterone,
and insulin-like growth factor 1 (IGF-I) were measured preoperatively
and on the sixth postoperative day. Serum morning cortisol was
measured on the third postoperative day (CORT3) as well as the sixth
postoperative day (CORT6). Tumor mass was measured preoperatively
and remission was assessed 3 months after surgery. An ITT was
performed 3 to 6 months postoperatively.
Remission was achieved in 48% of patients and AI occurred in 51%.
Remission rates and tumor type were not associated with AI. CORT3
had the best predictive value for AI (area under the curve (AUC) 0.868,
sensitivity 82.4%, specificity 83.3%). Tumor size, preoperative T4,
postoperative T4, and TSH were also associated with AI in a multi-
variate regression model. A combination of all preoperative and post-
operative variables (excluding serum cortisol) had a sensitivity of 75.0%
and specificity of 77.8%. The predictive power of CORT3 substantially
improved by adding those variables into the model (AUC 0.921,
sensitivity 94.1%, specificity 78.3%, PPV 81.9%, NPV of 92.7%). In
a subgroup analysis that included only female patients with NPA, LHD, Jelena Marink c, MD,
an Pecina, MD, PhD, and Milan Vrkljan, MD, PhD
Besides CORT3, tumor size, thyroid hormones, and gonadotropins
can serve as predictors of AI. LH in postmenopausal female patients
with NPA has similar diagnostic accuracy as CORT3. Further studies
are needed in order to validate the scoring system proposed by this
study.
(Medicine 95(9):e2898)
Abbreviations: AI = adrenal insufficiency, AUC = area under the
curve, CORT3 = serum morning cortisol on the third postoperative
day, CORT6 = serum morning cortisol on the sixth postoperative
day, FSH = follicle-stimulating hormone, HPA = hypothalamus–
pituitary–adrenal axis, IGF-I = insulin-like growth factor 1, ITT =
insulin tolerance test, LH = luteinizing hormone, MRI = magnetic
resonance imaging, NPA = nonfunctional pituitary adenoma,
NPV = negative predictive value, PPV = positive predictive
value, ROC = receiver operating characteristic, T3 = thyronin, T4 =
thyroxin, TSH = thyrotropin.
INTRODUCTION
P ituitary tumors and pituitary surgery are the most commoncauses of adrenal insufficiency (AI). Approximately 44% to
52% of patients will have AI after pituitary surgery.1,2 AI
requires hydrocortisone replacement therapy in order to avoid
adrenal crisis. The insulin tolerance test (ITT) is the gold
standard test for detecting AI3; however, there are several
disadvantages when using the ITT to assess the hypothala-
mic–pituitary–adrenal (HPA) axis. It is unpleasant for patients
and close medical supervision is required during testing. In
addition, it is contraindicated in patients with ischemic heart
disease, arrhythmias, or epilepsy, and can only be used in older
patients with caution.3 Although rare, dynamic pituitary testing
in patients with large adenomas can precipitate pituitary apo-
plexy.4 Hence, it may be inconvenient and dangerous to per-
form an ITT in the early postoperative period. Low dose and
standard dose synthetic ACTH stimulation tests are safe but
unreliable and should not be used in the early postoperative
period.5,6
Randomized control trials evaluating the appropriate post-
operative assessment and ideal replacement therapy have not
been conducted. Few studies have assessed the use of serum
morning cortisol in the early postoperative period as a predictor
of AI in order to select patients who require replacement
therapy.1,7 Unfortunately, these studies failed to accurately
detect AI in the largest group of patients that had serum cortisol
between 100 and 450 nmol/L. Current recommendations based
on small retrospective studies suggest that the early postopera-
tive assessment should include daily clinical examination asma cortisol levels.8 Cortisol levels over
mal HPA function, and levels less than
ent with ACTH deficiency. Patients with
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cortisol levels between 100 and 250 nmol/L may be ACTH
deficient and should receive morning hydrocortisone replace-
ment until definitive HPA axis testing. Patients with cortisol
levels between 250 and 450 nmol/L are unlikely to be ACTH
deficient but should receive additional steroids in times of stress
until a definitive test is performed.6,8
Corticotropic, thyrotropic, gonadotropic, somatotropic,
and lactotropic cells are scattered within the anterior pituitary
gland. Evidence suggests that injury to the anterior pituitary
rarely leads to isolated corticotropin deficiency.9 Deficiencies
of other hormonal axes and local tumor compressive symptoms
may accompany, precede, or follow AI.10 Thus, other pituitary
hormones and hormones of their target glands might also predict
the onset of AI. The aim of our study was to analyze whether
tumor size, remission rates, preoperative, and early postopera-
Cerina et altive baseline hormone concentrations could serve as predictors
of AI in order to increase the diagnostic accuracy of morning
serum cortisol.
PATIENTS AND METHODS
Study Protocol
This prospective observational study enrolled 70 consecu-
tive patients with newly diagnosed pituitary adenomas. Thirty-
seven patients had nonfunctional pituitary adenomas (NPA), 28
had prolactinomas and 5 patients had somatotropinomas.
Microprolactinomas were diagnosed in patients with adenomas
<10mm and serum prolactin (PRL) levels >70mg/L, and
macroprolactinomas in patients with adenomas >10mm and
serum PRL >100mg/L.11 Somatotropinomas were diagnosed
in patients with increased age-adjusted IGF-I concentrations
and GH >0.5 ng/mL during the oral glucose tolerance test
(OGTT).12 Cushing disease was diagnosed in patients with
increased morning serum cortisol, increased urinary-free corti-
sol and morning cortisol >50 nmol/L after an overnight 1mg
dexamethasone suppression test, along with normal or elevated
serum concentrations of ACTH.13 Patients who met the criteria
for Cushing disease were excluded from the study. Patients that
did not meet the previously mentioned criteria were diagnosed
with NPA.
All patients underwent magnetic resonance imaging (MRI)
of the sellar region using the standard protocol for pituitary
imaging. This included sagittal and coronal T1-weighted
images and T1 postcontrast images, as well as T2-weighted
images in the coronal plane. The same experienced neurora-
diologist (HIP) reviewed all MRI images in order to reduce
observer bias. The neuroradiologist was blinded to the clinical
information during MRI evaluation. Two days before surgery,
hormone measurements were obtained at 8 AM following an
overnight fast. The hormonal evaluation included measure-
ments of serum total T4, TSH, PRL, FSH, LH, testosterone
in men, IGF-I, morning serum cortisol, ACTH, and 24-hour
urinary-free cortisol. The same experienced neurosurgeon (VC)
operated the patients using the endoscopic transsphenoidal
approach.14 On the day of surgery, all patients received
100mg of hydrocortisone intravenously. Oral hydrocortisone
replacement therapy was continued in all patients at a dose of
20mg in the morning and 10mg at 5:00 PM. On the sixth
postoperative day, serum total T4, TSH, PRL, FSH, LH, tes-
tosterone in men, and IGF-I was measured. Serum morning (8
AM) cortisol was measured on the third postoperative day
(CORT3) as well as the sixth postoperative day (CORT6),
before patients took their morning dose of hydrocortisone.
2 | www.md-journal.comAn ITT was performed in all patients 6 to 9 months post-
operatively. Hydrocortisone replacement therapy was withheld
36 hours before testing and the ITTwas performed according to
standard protocol. Initial baseline cortisol and glucose levels
were measured though an indwelling cannula after 30minutes.
Insulin was administered at a dose of 0.1 to 0.2U/kg. Glucose,
cortisol and insulin levels were measured 10, 20, 30, 60, and
120minutes later. Patients with peak cortisol levels of
550 nmol/L, along with plasma glucose 2.2mmol/L were
considered to have normal adrenal function.
Remission was assessed on the third postoperative month
and was defined as the following: normalization of serum PRL 3
months after surgery in patients with prolactinomas; normal-
ization of IGF-I along with GH<0.5 ng/mL during the OGTT in
patients with somatotropinomas; absence of residual tumor
tissue on MRI in patients with NPA.
The ethics committee at the University Hospital Center
Sestre milosrdnice, ‘‘Eticˇko povjerenstvo’’ approved the study
and all patients gave written informed consent.
Hormonal Assays
PRL was measured using the flow injection analysis
method—reference range for men was 2.0 to 20.0mg/L and
for women 2.0 to 30.0mg/L. Electrochemiluminescence immu-
noassay was used for measurement of serum cortisol, growth
hormone (GH), insulin-like growth factor-I (IGF-I), follicle-
stimulating hormone (FSH), and luteinizing hormone (LH). The
reference ranges for morning cortisol, GH, IGF-I were 138 to
800 nmol/L, 0.0 to 0.5 ng/mL, and 115 to 420 ng/mL, respect-
ively. The reference range for FSH in the follicular phase was
3.5 to 12.5 IU/L for women in reproductive age, 25.8 to
134.8 IU/L for menopausal women, and 1.5 to 12.4 IU/L for
men. The reference range for LH in the follicular phase was 2.4
to 12.6 IU/L, 7.7 to 58.5 IU/L for menopausal women and 1.7 to
8.6 IU/L for men. The radioimmunoassay method was used to
determine the 24-hour urinary-free cortisol and testosterone.
The reference range for 24-hour urinary-free cortisol was 72.5
to 372.0 nmol/24 hours. The reference range for testosterone in
men aged 20 to 50 years was 8.6 to 29.0 nmol/L and in men
older than 50 years 6.7 to 25.7 nmol/L. Chemiluminescence
immunoassays were used for thyroid-stimulating hormone
(TSH), T4, and adrenocorticotropic hormone (ACTH) measure-
ment. Reference ranges were the following: for TSH 0.4 to
4.0mIU/L, for T4 60 to 165 nmol/L, and for ACTH 2.0 to
13.3 pmol/L.
Statistical Analyses
Patient characteristics were assessed using descriptive
statistics and presented as median values with interquartile
ranges. Independent continuous variables were compared using
Mann–Whitney test and categorical variables were compared
using Fisher exact test. Longitudinal values were reported as
median and interquartile range. The association between tumor
type, age, gender, and remission and the development of AI was
analyzed using binary and multinomial logistic regression when
appropriate. It was also used to adjust for confounding factors.
A linear mixed effects model was used to determine which
hormones were different in patients with and without AI. Since
the majority of hormones did not follow normal distribution,
they were all transformed by logarithm to base 10 before the
Medicine  Volume 95, Number 9, March 2016liner mixed effects model analysis. A linear mixed effects model
with AR-heterogeneous covariance structure was used to com-
pare the difference between patients with and without AI. The
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY)subject-specific intercept was considered a random effect, and
time, group, and time by group interaction were considered
fixed effects. Tumor size was also considered a fixed effect
covariate, adjusting for baseline individual differences. Mean
differences reported within the text present the difference of
log-transformed values for each variable. Mean differences are
results of linear mixed effects model analysis and compare the
magnitude of difference between the variables. Concentrations
of hormones and the true differences in hormone concentrations
are presented in Table 1. However, these differences are only
informative and we did not report P values for changes between
preoperative and postoperative concentrations. Variables that
were independently associated with AI were included in recei-
ver operating characteristic (ROC) analysis. ROC analysis was
performed on raw data, but only for parameters that showed
significant differences on linear mixed effect model analysis.
ROC analysis aimed to establish cut-off hormone concen-
trations and their sensitivity, specificity, positive, and negative
predictive values. Scoring system was developed based on z-
scores obtained from ROC analysis. The initial power analysis
was performed using the area under the curve (AUC) values
obtained from previous studies. When considering type 1 error
(a) to be 5% and type 2 error (b) to be 20%, the minimum
Medicine  Volume 95, Number 9, March 2016sample size was 20 (10 patients with AI and 10 patients without
AI). However, a larger sample size was needed, since we aimed
to analyze several other parameters, which have not been
TABLE 1. Characteristics of the Study Population Divided Based
Adrenal Insufficiency (N¼ 3
Age (y) 48.0 (33.5–58.5)
Tumor size (mm) 23.0 (16.0–30.0)
Remission, n (%) 40.0 (14)
Gender (male) % (n) 47.2 (17)
Tumor type
Somatotropinoma % (n) 5.6 (2)
Prolactinoma % (n) 36.1 (13)
Nonfunctional adenoma % (n) 58.3 (21)
PRL (mg/L) baseline 15.0 (11.8–25.6)
6th day 9.2 (3.3–15.3)
T4 (nmol/L) baseline 84.8 (68.5–97.6)
6th day 95.8 (80.7–111.2)
TSH (mIU/L) baseline 1.7 (1.1–2.8)
6th day 0.6 (0.3–1.2)
IGF-I (ng/ml) baseline 109.0 (64.6–152.0)
6th day 119.0 (74.3–175.0)
Testosterone (nmol/L) baseline 4.3 (0.4–9.2)
6th day 3.8 (0.6–10.1)
FSH (IU/L) baseline 4.6 (1.7–7.4)
6th day 4.0 (2.3–6.8)
LH (IU/L) baseline 1.6 (0.6–3.8)
6th day 1.8 (1.0–4.0)
Cortisol (nmol/L)
Baseline 360.5 (150.0–579.5)
CORT3 248.0 (115.0–340.7)
CORT6 256.0 (174.5–420.2)
Urinary-free cortisol (nmol/24h) 92 (41–167)
Continues variables are presented as median with interquartile ranges (2
CORT3¼morning cortisol on the 3rd postoperative day, CORT6¼mor
IGF-I¼ insulin-like growth factor 1, LH¼ luteinizing hormone, PRL¼ pro
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.analyzed previously. Our sample size of 70 patients with
patients divided in a 1:1 ratio based on the presence of AI,
had a power of 99% for 3rd day cortisol. Power was sufficiently
high for all associations with AUC 0.689 or greater. IBM SPSS
Prediction of Adrenal Insufficiency After Pituitary Surgerywas used to perform all analyses. P-value< 0.05 was
considered significant.
RESULTS
Anthropometric Characteristics
The study was performed from the year 2012 to 2013 and
included 42 women with a mean age of 38 years (range 30.0–
52.0) and 28 men with a mean age of 54 years (range 42.5–
61.0). Male patients were significantly older (P< 0.001), but
neither gender nor age was associated with AI. Patients had a
median tumor size of 20.0mm (range 10.0–27.5). Patients with
AI had significantly larger tumors (23mm vs 17mm,
P¼ 0.004). The association between tumor size and AI
remained significant in a logistic regression model adjusted
for tumor type (OR 1.070, 95% CI: 1.013–1.129, P¼ 0.015).
Remission was achieved in 48% of patients and AI occurred in
51% of patients. There was no statistically significant difference
in remission between certain types of tumors nor did AI depend
on tumor type (Table 1).
on the Presence of Adrenal Insufficiency
6) Without Adrenal Insufficiency (N¼ 34) P
47.0 (35.2–60.7) 0.796
17.0 (9.0–22.2) 0.004
57.6 (19) 0.231
32.4 (11) 0.231
0.644
8.8 (3)
44.1 (15)
47.1 (16)
9.1 (7.5–26.2) 0.655
4.7 (3.6–9.2) 0.258
97.5 (84.6–119.0) 0.008
118.0 (93.4–130.7) 0.022
2.1 (1.2–3.1) 0.342
1.2 (0.6–1.8) 0.013
143.5 (114.0–190.0) 0.039
180.0 (139.7–243.0) 0.017
8.7 (5.9–13.5) 0.059
7.0 (5.1–11.8) 0.200
8.4 (3.4–35.9) 0.016
5.2 (3.1–31.9) 0.052
5.5 (2.4–23.0) 0.001
7.1 (1.7–17.5) 0.003
476.0 (348.0–598.5) 0.062
491.0 (364.5–547.0) <0.001
461.0 (397.7–546.7) <0.001
145 (98–239) 0.041
5–75%).
ning cortisol on the 6th postoperative day, FSH¼ follicle-stimulating,
lactin, T4¼ thyroxin, TSH¼ thyrotropin.
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The Association Between Laboratory Parameters
and Development of AI
The gold standard test (ITT) was performed 6 to 9 months
postoperatively. AI was diagnosed in 36 (51%) patients, while
34 (49%) patients did not have AI. Patients with AI had
significantly lower preoperative T4, IGF-I, FSH, LH, 24-hour
urinary-free cortisol and lower postoperative T4, TSH, IGF-I,
LH, CORT3, and CORT6. There was no difference in other
parameters between the study groups (Table 1). In a linear
mixed model adjusted for age and tumor size, patients with AI
had significantly lower cortisol levels (mean difference0.238,
95% CI: 0.355 to 0.121, P< 0.001) (Figure 1A), T4 (mean
difference 0.104, 95% CI: 0.167 to 0.041, P¼ 0.002)
(Figure 1B), and TSH (mean difference 0.257, 95% CI:
0.472 to 0.042, P¼ 0.02) (Figure 1C). The association
between baseline 24-hour urinary-free cortisol and AI dimin-
ished after adjustment for tumor size.
T4 levels significantly increased after the surgery (mean
difference 0.032, 95% CI: 0.001–0.063, P¼ 0.046), whereas
TSH decreased (mean difference 0.325, 95% CI: 0.481 to
0.168, P< 0.001). After additional adjustment for tumor type,
serum PRL decreased in NPA (mean difference 0.446, 95%
CI: 0.591 to 0.300, P< 0.001), but substantially more in
Cerina et alprolactinomas (mean difference 0.768, 95% CI: 1.020 to
0.515, P< 0.001). There were no differences in serum PRL
levels in patients with and without AI. Serum IGF-I increased
FIGURE 1. Linear mixed model analysis adjusted for tumor size show
between patients with adrenal insufficiency (interrupted line) and wi
4 | www.md-journal.comafter surgery (mean difference 0.078, 95% CI: 0.014–0.141,
P¼ 0.018), but it was not correlated with AI. After adjustment
for tumor size, there were no differences between study groups.
Overall, serum FSH and LH levels were lower in patients
with AI. Female patients with prolactinomas had significantly
lower baseline FSH (6.3 vs 22.3, P¼ 0.018) and lower post-
operative FSH (4.9 vs 22.9, P¼ 0.004) and LH (4.8 vs 12.2,
P¼ 0.027). Therefore, gonadotropins were analyzed separately
in patients with prolactinomas. In patients with prolactinomas,
there was no difference in FSH, LH, and testosterone levels in
those with and without AI. However, female patients with NPA
and AI had significantly lower serum LH (mean difference
1.065, 95% CI: 1.672 to 0.458, P¼ 0.002) (Figure 1D)
and FSH (mean difference0.863, 95% CI:1.207 to0.520,
P< 0.001) levels.
ROC Analysis and Scoring System
The sensitivity, specificity, positive, and negative predic-
tive value for each parameter are presented in Table 2. CORT3
had the best predictive value for AI (AUC 0.868, 95% CI:
0.727–0.954). However, in a subgroup analysis of female
patients with NPA, both preoperative and postoperative LH
had exactly the same predictive value as CORT3 (Figure 2).
Medicine  Volume 95, Number 9, March 2016In order to make our results more clinically applicable, we
developed a scoring system based on z scores derived from
ROC analysis. Each variable was labeled as follows: tumor
ing the changes in serum cortisol (A), T4 (B), TSH (C), and LH (D)
thout adrenal insufficiency.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Results of ROC Analysis Showing the Sensitivity, Specificity, Positive, and Negative Predicitive Values for Each Cut-Off
Value of the Variable
AUC
95% CI
for AUC
Cut-Off
Value
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Tumor size 0.694 0.570–0.801 <9 91.9 30.0 57.7 78.1
>19 67.6 63.3 65.7 65.2
> 29 35.1 93.3 84.5 58.0
T4 baseline 0.665 0.538–0.776 69.9 27.8 90.0 74.3 54.5
93.7 69.4 60.0 64.4 65.3
123 94.4 20.0 55.1 77.4
T4 6th day 0.662 0.529–0.778 81 26.7 93.6 81.3 55.1
114 83.3 54.8 65.7 75.9
134 90.0 19.4 52.0 56.5
TSH 6th day 0.670 0.538–0.785 0.43 36.7 90.3 79.7 57.8
1.24 80.0 48.4 61.7 69.9
1.96 93.3 22.6 56.6 78.6
CORT3 0.868 0.727–0.954 248 52.9 95.8 92.8 65.9
343 82.4 83.3 83.7 82.0
464 100.0 58.3 71.4 100.0
CORT6 0.780 0.642–0.884 320 62.5 94.7 92.5 70.8
515 90.6 36.8 59.9 79.0
LH baseline

0.868 0.618–0.981 3.4 77.8 87.5 86.6 79.1
5.2 100.0 75.0 80.6 100.0
LH 6th day

0.854 0.645–0.965 5.3 80.0 92.3 91.5 81.6
14.3 90.0 69.2 75.3 86.9
CORT6þ all baseline and postoperative 0.867 0.743–0.946 >2.5 96.8 20.0 55.7 85.7
>7.9 80.0 90.0 88.1 74.9
>11 35.5 100.0 100.0 59.8
CORT3þ all baseline and postoperative 0.921 0.790–0.982 >5.3 100.0 56.5 70.5 100.0
>7.9 94.1 78.3 81.9 92.7
>11 76.5 95.7 94.9 79.6
Baseline and postoperative 0.788 0.657–0.887 0 100.0 22.2 57.2 100.0
>5.3 75.0 77.8 77.9 74.9
>11 0.0 100.0 100.0 NA
Baseline parameters 0.728 0.591–0.839 0 100.0 0.0 NA 100.0
>3.1 53.6 85.2 79.0 63.8
>5.9 0.0 100.0 100.0 NA
CORT3þ baseline LH 0.944 0.669–1.000 >11 100.0 88.9 90.4 100.0
Baseline and postoperativeþ baseline LH 0.889 0.596–0.993 >5.9 100.0 77.8 82.4 100.0
>12.9 50.0 100.0 100.0 65.8
AUC¼ area under the curve, CI¼ confidence interval, CORT3¼morning cortisol on the 3rd postoperative day, CORT6¼morning cortisol on the
6th postoperative day, LH¼ luteinizing hormone, NA¼ not analysed, NPV¼ negative predictive value, PPV¼ positive predictive value,
T4¼ thyroxin, TSH¼ thyrotropin.
Medicine  Volume 95, Number 9, March 2016 Prediction of Adrenal Insufficiency After Pituitary Surgerydiameter >19mm as 3.1, baseline T4< 93.7 nmol/L as 2.8,
CORT3< 343 nmol/L as 6.2, CORT6< 320 nmol/L as 4.2,
postoperative T4< 114 nmol/L as 2.5, postoperative
TSH< 0.93mIU/L as 2.6 and baseline LH in females with
NF adenoma< 5.2 IU/L as 7.0. A score calculated based on
the combination of all preoperative and postoperative variables
excluding serum cortisol, yielded a similar predictive value as
CORT3 (AUC 0.788, 95% CI: 0.657–0.887). Moreover, the
predictive power of CORT3 substantially improved by adding
other variables into the model (AUC 0.921, 95% CI: 0.790–
0.982). A score of 7.9 had a sensitivity of 94.1%, specificity of
Females with nonfunctional adenomas.78.3%, PPV of 81.9%, and NPV of 92.7% (Figure 2). In female
patients with NPA, when baseline LH was added to the other
variables the AUC increased to 0.944 (95% CI: 0.669–1.000).
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.A score of 11 had a sensitivity of 100.0%, specificity of 88.9%,
PPV of 90.4%, and NPV of 100.0%.
DISCUSSION
Our study is the first to demonstrate that tumor size,
thyroid hormones, and gonadotropins can be used to predict
the development of AI after pituitary surgery in postmenopausal
women with NPA. Moreover, a combination of these
parameters and LH levels alone, have a similar diagnostic value
as CORT3.Two previous studies observed an association between
postoperative serum morning cortisol and the development of
AI. In a small retrospective study by Jayasena et al a cut-off
www.md-journal.com | 5
FIGURE 2. ROC curves showing the sensitivity and specificity of CORT3 (A); tumor size and preoperative T4 (interrupted line), tumor size,
the
s (C
Cerina et al Medicine  Volume 95, Number 9, March 2016cortisol concentration of 300 nmol/L on the 5th postoperative
day had a 86.9% diagnostic sensitivity and a 69.2% diagnostic
specificity7. In our study, CORT3< 343 nnol/L had an 82.4%
sensitivity and an 83.3% specificity, while CORT6< 320 nmol/
L had a 62.5% sensitivity and a 94.7% specificity. Our study is
the first to demonstrate a difference between cut-off cortisol
levels and time of cortisol measurement, suggesting that cortisol
measured within the first 3 days after surgery might be a better
predictor of AI. In a study by Karaca et al, morning serum
cortisol was measured on the 2nd, 3rd, 4th, 5th, and 6th post-
operative day. The authors reported only lower cut-off values
with 100% specificity, but did not report cut-off values with the
best sensitivity and specificity (based on Youden index) nor did
they report AUC values. However, morning cortisol cut-off
concentrations with 100% specificity ranged from 193 nmol/L
(second and third postoperative day) to 83 nmol/L (sixth post-
operative day). The various cut-off levels used on different days
further demonstrates the importance of timing when measuring
cortisol.1 All patients included in our study were prescribed with
hydrocortisone replacement therapy after surgery and the poten-
tial influence of glucocorticoid replacement therapy on morning
cortisol cut-off values may be questioned. Because glucocorti-
coid replacement therapy increases serum cortisol levels, higher
cortisol cut-off values might be expected in these patients. In a
study by Jayasena et al all patients received glucocorticoid
replacement therapy, while in a study by Karaca et al only
patients with preoperatively diagnosed AI with ITT received
glucocorticoid replacement therapy. Surprisingly, morning cor-
tisol cut-off values with 100% specificity were higher in Karaca
study (165 vs 111 nmol/L).
The cut-off cortisol values with 100% specificity in our
study are comparable with those in Karaca study, which
suggests that cut-off values are not influenced by glucocorticoid
replacement therapy.
Our study disclosed several new insights on pituitary
function in the early postoperative period. Although the corre-
lation between tumor size and AI may be obvious, our study is
first to determine the true prognostic value of tumor size in
prediction of AI. Remission implies more radical tumor resec-
tion and potentially more pronounced pituitary injury. How-
preoperative T4 and postoperative T4 and TSH (dotted line) and
preoperative LH in female patients with nonfunctioning adenomaever, there was no correlation between remission rates and AI.
The main goal of our study was to determine whether other
pituitary and target gland hormones could predict AI.
6 | www.md-journal.comPreoperative T4, LH, FSH and postoperative T4, TSH, LH,
and FSH were associated with AI after adjustment for tumor
size. This finding is interesting and could substantially change
the evaluation of the HPA axis. The HPA axis is a critical stress-
responsive system with prominent circadian rhythmicity, with
highest cortisol levels at 8:00 AM and lowest levels during the
night.15 During severe stress, a 10-fold increase in cortisol may
occur.16 This is why a single cortisol measurement is not a
reliable indicator of the HPA axis. GH has similar physiological
properties but IGF-I has a more favorable half-life (12–
15 hours).17 However, dynamic tests are required for adequate
evaluation of somatotropic function as well. On the other hand,
thyroid hormones and sex hormones in males and postmeno-
pausal women do not exhibit any circadian rhythmicity.18,19
Hence, basal endocrinological testing is usually adequate for
proper evaluation of thyroid and gonadal function. Since corti-
cotropic, thyrotropic, gonadotropic, somatotropic, and lacto-
tropic cells are scattered within the anterior pituitary gland, it
may be justifiable to use thyrotropic and gonadotropic hor-
mones to indirectly evaluate corticotropic and somatotropic
function. Our study is the first to report that thyroid hormones
and gonadotropins can be used as indicators of HPA axis
function. A combination of tumor size, preoperative T4, post-
operative T4, and TSH had a sensitivity of 75.0% and speci-
ficity of 77.8%. Similar findings were observed using only
CORT3. Moreover, the addition of these parameters to CORT3,
increased sensitivity to 94.1% and specificity to 78.3%. Inter-
estingly, preoperative LH in postmenopausal women with NPA
had a sensitivity of 100.0%, specificity of 75.0% and an AUC
identical to CORT3. In premenopausal female patients LH was
not associated with AI, possibly due to different stages of the
menstrual cycle in which LH was measured and the additional
suppressive effect of hyperprolactinemia. In male patients, this
association could not be elucidated due to the relatively small
sample size in the subgroup analyses.
Finally, we wish to comment on changes in T4, TSH, IGF-
I, and PRL levels. Previous studies have documented a drop in
serum PRL levels both in patients with prolactinomas and NPA
immediately after surgery.20 In patients with prolactinomas, this
effect is explained by the reduction of PRL-secreting tumor
combination of CORT3 with all the latter variables (full line) (B);
).tissue. In patients with NPA, the drop in PRL follows restoration
of hypothalamic control over pituitary hormone secretion which
leads to increased dopamine flow to the anterior pituitary;
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
therefore, changes in serum PRL in patients with NPA may
serve as an indicator of overall pituitary function. Although a
significant decrease in PRL levels occurred in patients with
prolactinomas and NPAs in our study, we found no association
between serum PRL and AI. The immediate postoperative
increase in IGF-I we observed implies an overall improved
pituitary function. The dynamics of thyroid hormones in our
study remain elusive. The increase in total T4 and decrease in
TSH could be explained by the interference of anesthetics,
which could affect thyroid hormone binding proteins or per-
ipheral conversion of T4 to T3. Unfortunately, free thyroid
hormone levels were not determined and these questions need to
be answered in future studies.
A limitation of our study was the small study population;
therefore, we could not divide our population into 2 groups.
Ideally, one group should have been used to develop the scoring
system, and the other group to test the power of the proposed
scoring system in a separate series of patients. Thus, future
studies are needed to validate our scoring system in a different
patient population.
In conclusion, our study has confirmed the role of basal
cortisol measurement in the early postoperative period in pre-
dicting AI. CORT3 is a better predictor of AI than CORT6.
Preoperative tumor size, perioperative thyroid hormones, and
gonadotropins can serve as predictors of AI. Preoperative LH in
postmenopausal female patients with NPA has similar diag-
nostic accuracy as CORT3.
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